IN8bio's INB-200 Achieves Promising Results in Phase 1 GBM Trial, Boosting Long-Term Survival Rates

IN8bio's INB-200 has achieved a key milestone in its Phase 1 trial for GBM, with a patient experiencing 4 years of remission. The treatment has shown a strong safety profile and promising long-term benefits, with a median progression-free survival of 16.1 months. Analysts forecast an average target price of $107.70, with a high estimate of $225.00 and a low estimate of $36.00, indicating a potential upside of 2,482.73% from the current price of $4.17.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, has reported a significant milestone in its Phase 1 trial for glioblastoma (GBM) with its gamma-delta T cell therapy, INB-200. Patient 009, who received INB-200 treatment, has achieved 4 years of remission [1]. This remarkable outcome surpasses the progression-free survival (PFS) observed in other clinical trials for IDH-mutant glioma patients.

The patient, diagnosed with a grade 4, IDH-mutant glioma, has not only survived but also returned to work and maintained a good quality of life. Dr. Burt Nabors, Principal Investigator of the INB-200 trial, emphasized the potential of gamma-delta T cells in treating aggressive cancers like GBM [2].

IN8bio recently presented updated Phase 1 data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating that repeated doses of INB-200 extended median PFS to 16.1 months, more than double the 6.9 months typically seen with the standard-of-care Stupp protocol [2]. The therapy has shown a favorable safety profile and signals of long-term benefits.

Analysts have forecasted an average target price of $107.70 for IN8bio, with a high estimate of $225.00 and a low estimate of $36.00. This indicates a potential upside of 2,482.73% from the current price of $4.17 [3].

References:
[1] https://www.biospace.com/press-releases/in8bio-recognizes-achievement-of-4-years-in-remission-for-patient-treated-with-inb-200-in-glioblastoma-trial
[2] https://www.globenewswire.com/news-release/2025/06/09/3095724/0/en/IN8bio-Recognizes-Achievement-of-4-Years-in-Remission-for-Patient-Treated-with-INB-200-in-Glioblastoma-Trial.html